Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralf Gold

Showing results (21-30 of 700) with videos related to

Pageof 70
Sort By:
The American Journal of Pathology|April 17, 2010
The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulationAiden Haghikia, Ralf Gold
Experimental Neurology|April 23, 2014
Multiple sclerosis: insights into pathophysiology and novel therapeutic avenuesRalf Gold, Lars Fugger
Experimental Neurology|February 27, 2014
Mode of action and clinical studies with fumarates in multiple sclerosisAnke Salmen, Ralf Gold
Neurological Research and Practice|December 16, 2020
Severe pneumonia with formation of a pulmonary cavity associated with long-term rituximab therapy in multiple sclerosisCarolin Schwake, Ralf Gold
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 24, 2018
Clinical commentary on 'Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis'Simon Faissner, Ralf Gold
Journal of Neuroimmunology|November 23, 2007
Many roads lead to Rome: heterogeneity among encephalitogenic T cell clonesFred Lühder, Ralf Gold
CNS Drugs|March 31, 2018
Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010Simon Faissner, Ralf Gold
Journal of Neuroimmunology|November 3, 2009
Sphingosine-1-phosphate and its receptors as a possible therapeutic target in autoimmune diseases of the nervous systemAiden Haghikia, Ralf Gold
Journal of Neurology|September 30, 2010
Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosisKerstin Hellwig, Ralf Gold
CNS Drugs|May 26, 2018
Correction to: Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010Simon Faissner, Ralf Gold
Pageof 70

Showing results (21-30 of 700) with videos related to

Sort By:
Pageof 70
The American Journal of Pathology|April 17, 2010
The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulationAiden Haghikia, Ralf Gold
Experimental Neurology|April 23, 2014
Multiple sclerosis: insights into pathophysiology and novel therapeutic avenuesRalf Gold, Lars Fugger
Experimental Neurology|February 27, 2014
Mode of action and clinical studies with fumarates in multiple sclerosisAnke Salmen, Ralf Gold
Neurological Research and Practice|December 16, 2020
Severe pneumonia with formation of a pulmonary cavity associated with long-term rituximab therapy in multiple sclerosisCarolin Schwake, Ralf Gold
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 24, 2018
Clinical commentary on 'Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis'Simon Faissner, Ralf Gold
Journal of Neuroimmunology|November 23, 2007
Many roads lead to Rome: heterogeneity among encephalitogenic T cell clonesFred Lühder, Ralf Gold
CNS Drugs|March 31, 2018
Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010Simon Faissner, Ralf Gold
Journal of Neuroimmunology|November 3, 2009
Sphingosine-1-phosphate and its receptors as a possible therapeutic target in autoimmune diseases of the nervous systemAiden Haghikia, Ralf Gold
Journal of Neurology|September 30, 2010
Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosisKerstin Hellwig, Ralf Gold
CNS Drugs|May 26, 2018
Correction to: Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010Simon Faissner, Ralf Gold
Pageof 70